Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
ExonHit Therapeutics
ExonHit files patent on a panel of genes for the diagnosis of Alzheimer disease from blood
June 23rd, 2006
ExonHit Therapeutics, a drug and diagnostic discovery company, announced that it has filed a patent with the French Intellectual Property Institute (INPI) which covers a panel of genes that could enable the differential diagnosis of Alzheimer patients from blood. The use of these genes will allow the identification of patients suffering from Alzheimer disease from a population of elderly patients with no signs of cognitive disorders. This is an important development as there is currently no diagnostic test that can accurately identify patients with Alzheimer disease. The diagnosis of Alzheimer disease is determined by default after an in-depth...
Source: Biotech Law Weekly (2006-06-23)
|
